J
Jack Ansell
Researcher at Lenox Hill Hospital
Publications - 61
Citations - 9963
Jack Ansell is an academic researcher from Lenox Hill Hospital. The author has contributed to research in topics: Warfarin & Apixaban. The author has an hindex of 26, co-authored 61 publications receiving 9004 citations. Previous affiliations of Jack Ansell include Duke University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Journal ArticleDOI
Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
Renato D. Lopes,John H. Alexander,Sana M. Al-Khatib,Jack Ansell,Raphael Diaz,J. Donald Easton,Bernard J. Gersh,Christopher B. Granger,Michael G. Hanna,John D. Horowitz,Elaine M. Hylek,John J.V. McMurray,Freek W.A. Verheugt,Lars Wallentin +13 more
TL;DR: The primary objective of ARISTOTLE is to determine if the factor Xa inhibitor, apixaban, is noninferior to warfarin at reducing the combined endpoint of stroke (ischemic or hemorrhagic) and systemic embolism in patients with AF and at least 1 additional risk factor for stroke.
Journal ArticleDOI
Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
Sean D. Pokorney,Sean D. Pokorney,DaJuanicia N Simon,Laine Thomas,Gregg C. Fonarow,Peter R. Kowey,Paul Chang,Daniel E. Singer,Jack Ansell,Rosalia Blanco,Bernard J. Gersh,Kenneth W. Mahaffey,Elaine M. Hylek,Alan S. Go,Jonathan P. Piccini,Jonathan P. Piccini,Eric D. Peterson,Eric D. Peterson +17 more
TL;DR: Among patients with AF in US clinical practices, TTR on warfarin is suboptimal, and those at highest predicted risks for stroke and bleeding were least likely to be in therapeutic range.
Journal ArticleDOI
Direct thrombin inhibitors.
Catherine J. Lee,Jack Ansell +1 more
TL;DR: Of the new oral DTIs, dabigatran etexilate is the most studied and promising of these agents and future directions in anticoagulant therapy are discussed.
Journal ArticleDOI
Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation
Lars Wallentin,Renato D. Lopes,Michael G. Hanna,Laine Thomas,Anne S. Hellkamp,Sunil Nepal,Elaine M. Hylek,Sana M. Al-Khatib,John H. Alexander,Marco Alings,John Amerena,Jack Ansell,Philip E. Aylward,Jozef Bartunek,Patrick J. Commerford,Raffaele De Caterina,Çetin Erol,Veli-Pekka Harjola,Claes Held,John D. Horowitz,Kurt Huber,Steen Husted,Matyas Keltai,Fernando Lanas,Liu Lisheng,John J.V. McMurray,Byung Hee Oh,Mårten Rosenqvist,Witold Rużyłło,Philippe Gabriel Steg,Dragos Vinereanu,Denis Xavier,Christopher B. Granger +32 more
TL;DR: The benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers’ and patients’ predicted quality of international normalized ratio control.